Chelsy Moore
Nurse Practitioner · Greensburg, PANPI 1437780715
Payments from drug & device makers
Across 204 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$520
- AstraZeneca$403
- GSK$337
- Novartis$237
- Lilly USA, LLC$206
- Bayer$194
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,315100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $520 |
| AstraZeneca | 20 | $403 |
| GSK | 23 | $337 |
| Novartis | 16 | $237 |
| Lilly USA, LLC | 13 | $206 |
| Bayer | 12 | $194 |
| AbbVie | 11 | $157 |
| Boehringer Ingelheim | 10 | $156 |
| Pfizer | 9 | $150 |
| Boston Scientific | 6 | $134 |
| E.r. Squibb & Sons, L.L.C. | 6 | $103 |
| Amarin Pharma, Inc. | 6 | $95 |
| Amgen | 5 | $74 |
| Johnson & Johnson | 4 | $70 |
| Ultragenyx Pharmaceutical Inc. | 3 | $63 |
| Merck | 3 | $45 |
| Teva Pharmaceuticals USA, Inc. | 3 | $42 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Edwards Lifesciences | 1 | $34 |
| Dexcom, Inc. | 2 | $32 |
| Astellas Pharma US Inc | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Axonics, Inc. | 1 | $20 |
| Exact Sciences | 1 | $20 |
| Abiomed | 1 | $18 |
| Lantheus Medical Imaging, Inc. | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Philips North America LLC | 1 | $13 |
How this compares
$3,315 in reported general payments places this provider in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 126 | $98,443 |
| OzempicSemaglutide | 65 | $64,372 |
| EliquisApixaban | 48 | $38,177 |
| XareltoRivaroxaban | 22 | $22,838 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $22,410 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $18,745 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $16,250 |
| JardianceEmpagliflozin | 15 | $16,169 |
| TrulicityDulaglutide | 15 | $14,997 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $7,471 |
| JanuviaSitagliptin Phosphate | 12 | $6,983 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $6,821 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $6,406 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,909 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $3,783 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $403 | $120,854161 claims |
| Novo NordiskOzempic | $520 | $64,37265 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $337 | $39,90472 claims |
| PfizerEliquis | $150 | $38,17748 claims |
| Johnson & JohnsonXarelto | $70 | $22,83822 claims |
| Boehringer IngelheimJardiance | $156 | $16,16915 claims |
| Lilly USA, LLCTrulicity | $206 | $14,99715 claims |
| MerckJanuvia, Janumet | $45 | $13,80424 claims |
| AbbVieSynthroid | $157 | $77522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Other nurse practitioner in Greensburg
- Amy AlexanderGreensburg$42K
- Patricia ManganPhiladelphia$360K
- Lisa CocoPhiladelphia$230K
- Elisabeth BaidalPhiladelphia$151K
- Suzanne McGettiganPhiladelphia$108K
- Tracey WileyChambersburg$101K
- Pamela LorditchJohnstown$81K
- Nana BernaskoHershey$81K
- Dawn JeanneratClarion$78K
- Carolyn GrandePhiladelphia$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.